Clinical Trial Update: A Safety Study of ABI-007 for In-Stent Restenosis [Phase 2]

View source ↗

Summary

Phase 2 safety study of ABI-007 for in-stent restenosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina
• Coronary Artery Disease

Drugs mentioned

• ABI-007 (nab-paclitaxel)

Snippet

Sponsor: Celgene | Conditions: Angina Pectoris, Coronary Artery Disease | Phase 2 | Status: COMPLETED